Antigen–IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα
Heydar Moravej(Dana-Farber Cancer Institute), Mohammad Rashidian(Harvard University)
Cited by 0
Related Papers
Noninvasive imaging of immune responses
|Proceedings of the National Academy of Sciences|2015|222